For US Residents Only

Welcome to the PROMACTA Patient Site

Welcome to the PROMACTA Patient Site

Approved Use:

PROMACTA is a thrombopoietin receptor agonist indicated for the treatment of:

  • thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
  • thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
  • patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.